In what is described as the "first of its kind" deal in Canada, ScheringAG subsidiary Berlex Canada and Mallinckrodt Medical Canada have announced a strategic partnership, whereby Berlex is transferring the sales and marketing responsibility for its two radiographic contract media, Ultravist and Osmovist, to Mallinckrodt. Conversely, Mallinckrodt will collaborate with Berlex to strengthen the latter's magnetic resonance imaging leadership with existing and future products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze